Strategic partnerships Radius Health has a recent in-licensing agreement with Pharmanovia for osteoporosis treatment abaloparatide ( marketed as TYMLOS in the U.S. ), highlighting a potential openness to collaboration on expanded indications, lifecycle management, or regional distribution partnerships in bone health.

Leadership turnover Significant C-suite changes in 2026 with departures of Chief Legal Officer and Chief Financial Officer, indicating a period of strategic realignment and potential access to new decision-makers for corporate partnerships, financing, or licensing discussions.

Global focus The company positions itself to serve underserved global patient populations in bone health, suggesting opportunities to tailor partnerships around access programs, affordability initiatives, and collaborative studies in emerging markets.

Strategic positioning Recognition as a TIME 100 Influential Company and as a leading sustainable company in 2023 reinforces credibility with health systems and payers, supporting conversations around value-based pricing, patient access programs, and sustainability-aligned partnerships.

Scale and reach With hundreds of employees and a revenue range in the hundreds of millions, Radius Health sits in the mid-to-large biotech space, presenting opportunities for co-development, supply agreements, or strategic ventures with larger pharma partners seeking bone-health franchises.